EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)

Veronica Mollica, Francesco Massari, Kazutoshi Fujita, Patrizia Giannatempo, Enrique Grande, Thomas Büttner, Maria T Bourlon, Tarek Taha, Wataru Fukuokaya, Zin W Myint, Renate Pichler, Kirstin Binz und 19 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04328-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Veronica Mollica und 30 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Avelumab, pembrolizumab, and enfortumab vedotin (EV) demonstrated efficacy in mUC following platinum-based chemotherapy. However, real-world data in patients with urothelial carcinoma with squamous differentiation (UCSD) are limited. The aim of this study is to assess the real-world clinical outcomes of avelumab, pembrolizumab, or EV in mUCSD patients. Materials and methods The ARON-2EV study is a retrospective, international, multicenter analysis in patients with mUC treated with avelumab, pembrolizumab, or EV across 79 centers in 21 countries. Patients were divided into three cohorts: 1 (avelumab), 2 (pembrolizumab), and 3 (EV). Primary endpoints were overall survival (OS) and time on treatment (ToT). Secondary objectives included evaluating clinical factors associated with outcomes and exploring the impact of UCSD histology on response to therapy. Statistical methods included Kaplan–Meier estimates, log-rank tests, Fisher’s exact and chi-square tests, and Pearson’s correlation coefficients.

Results

A total of 1918 patients, 1696 with advanced pure UC (pUC) and 222 with mUCSD (36 in cohort 1, 111 in cohort 2, and 75 in cohort 3), were included. Median OS was shorter in patients with UCSD compared to patients with pUC histology in the three cohorts (1: 13.0 vs 26.8 months, HR 2.66, p = 0.003; 2: 10.2 vs 18.5 months, HR 1.52, p = 0.008; and 3: 7.6 vs 13.1 months, HR 1.68, p = 0.011). Median ToT was shorter in patients with UCSD compared to patients with pUC histology in cohort 1 (3.5 vs 5.6 months, HR 1.57, p = 0.044) and 3 (7.6 vs 13.6 months, HR 1.83, p = 0.005) but not in cohort 2 (3.7 vs 4.7 months, HR 1.19, p = 0.177). Response to therapy was negatively correlated with UCSD histology in cohorts 2 (correlation coefficient 0.094, p = 0.008) and 3 (correlation coefficient 0.107, p = 0.021), while response to avelumab was not correlated with UCSD (correlation coefficient 0.072, p = 0.263).

Conclusions

UCSD is a histology with a poor prognosis and response to treatments compared to pUC. Treatments activity and effectiveness in divergent differentiations should be addressed in dedicated prospective studies. Trial registration number NCT05290038

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalCarcinoma, Squamous CellCarcinoma, Transitional CellUrinary Bladder NeoplasmsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedAged, 80 and overTreatment OutcomeAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

AvelumabEnfortumab VedotinImmunotherapyNCT05290038PembrolizumabSquamous differentiationUrothelial Carcinoma

Substanzen

Antibodies, Monoclonal, HumanizedavelumabpembrolizumabAntibodies, Monoclonalenfortumab vedotinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. francesco.massari8@unibo.it.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. francesco.massari8@unibo.it.
  • Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
  • Dipartimento Di Oncologia Medica, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Mollica, V., Massari, F., Fujita, K., Giannatempo, P., Grande, E., Büttner, T., Bourlon, M. T., Taha, T., Fukuokaya, W., Myint, Z. W., Pichler, R., Binz, K., Molina-Cerrillo, J., Kopecky, J., de Liaño, A. G., Kucharz, J., Fiala, O., Matrana, M. R., Kopp, R. M., …, & Santoni, M. (2026). Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04328-9

Vancouver

Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, et al. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04328-9

BibTeX
@article{Mollica2026,
  author = {Mollica, Veronica and Massari, Francesco and Fujita, Kazutoshi and Giannatempo, Patrizia and Grande, Enrique and Büttner, Thomas and Bourlon, Maria T and Taha, Tarek and Fukuokaya, Wataru and Myint, Zin W and Pichler, Renate and Binz, Kirstin and Molina-Cerrillo, Javier and Kopecky, Jindrich and de Liaño, Alfonso Gómez and Kucharz, Jakub and Fiala, Ondřej and Matrana, Marc R and Kopp, Ray Manneh and Di Civita, Mattia Alberto and Zgura, Anca and Ansari, Jawaher and Kihnel, Randi and De Felice, Francesca and Angel, Martín and Monteiro, Fernando Sabino M and Soares, Andrey and Urun, Yuksel and Buti, Sebastiano and Santini, Daniele and Santoni, Matteo},
  title = {Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04328-9}
}
Kostenlos starten →